epcoritamab + pirtobrutinib

**epcoritamab + pirtobrutinib** is a combination therapy under investigation primarily for relapsed/refractory and treatment-naïve high-risk chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), as well as considered for Richter’s Syndrome. - **Epcoritamab** is a humanized bispecific IgG1 monoclonal antibody that engages both CD3 (on T-cells) and CD20 (on B-cells), promoting T-cell activation, release of proinflammatory cytokines, and selective T-cell–mediated cytotoxic activity against malignant B-cells[4]. - **Pirtobrutinib** is a highly selective, non-covalent small molecule inhibitor of Bruton’s tyrosine kinase (BTK), blocking B-cell receptor signaling, which is critical for B-cell development and proliferation. It provides efficacy in BTK wild-type and mutant (C481S) cells and is effective in B-cell malignancies resistant to covalent BTK inhibitors[2][6]. The combination is currently being evaluated in clinical trials for its safety, tolerability, and efficacy particularly in high-risk CLL populations[1][3][5][7].

Other names

DuoBody-CD3xCD20 + pirtobrutinib